Massive Dilution Looms: Biotricity Creates Series C Preferred Stock Convertible to 59.6% of Equity After $15M Raise
summarizeSummary
Biotricity has implemented a significant capital restructuring, creating Series C Preferred Stock and swapping 14.1 million common shares, options, and warrants into 1.96 million Series C shares. Critically, these Series C shares will automatically convert into 59.6% of the company's outstanding common stock upon a qualified equity financing of at least $15 million. For a company with a market capitalization of approximately $7.5 million, this potential $15 million raise, leading to nearly 60% dilution, is an extremely material and negative event for existing common shareholders. This strategic move likely aims to address the company's previously disclosed "going concern qualification" by securing vital funding, but at a substantial cost to current equity holders. Traders should closely monitor the terms and completion of this highly dilutive financing.
At the time of this announcement, BTCY was trading at $0.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.20 to $0.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.